- Mabion and Novavax have signed an amendment extending their contract manufacturing agreement by three years, with the collaboration now continuing through the end of 2029.
- Under the extended agreement, Mabion will continue providing commercial manufacturing, process development, analytical services, and quality assurance support to Novavax.
Mabion S.A. and Novavax have signed an amendment extending their contract manufacturing agreement by three years, continuing the collaboration until the end of 2029. The companies stated that the extension builds on a partnership that began in 2021.
Under the terms of the extended agreement, Mabion will continue to provide a range of services to Novavax, including commercial contract manufacturing, process development, analytical services, and quality assurance support. The services will be delivered in line with Novavax’s requirements.
The companies said the extension reflects the ongoing relationship between the two organizations and supports Novavax’s manufacturing and development activities. Mabion noted that the agreement reinforces its role in supporting biopharmaceutical companies through manufacturing and technical services.
The continued cooperation also aligns with Mabion’s business strategy and its focus on biologics development and manufacturing. The company stated that it will continue contributing its capabilities through the extended partnership.
The agreement extends a collaboration that has been in place since 2021 and ensures the continuation of contract manufacturing and related support services through 2029.
